Portland, OR Clinical Trials Report — July 2026

Portland participants should act now if they are considering a study scheduled to close soon: 39 recruiting trials are expected to close within the next 90 days, including 8 that accept healthy volunteers. Portland currently has 971 recruiting trials across 319 research facilities, but enrollment may end earlier if a study reaches its participant target.

July added 9 new trials, down from 15 in May and June. None of the new July studies accept healthy volunteers, although 72 recruiting studies in Portland are available to healthy participants overall.

Closing windows are concentrated in cancer and immune conditions

People with the conditions below should contact study teams promptly and confirm that Portland enrollment remains open. The closing-soon list includes:

• Atopic dermatitis (2 trials)
• Endometrial cancer (2 trials)
• Ovarian cancer (2 trials)
• Advanced solid tumor (2 trials)
• Prostate cancer (2 trials)
• Metastatic solid tumor (2 trials)
• Chemotherapy-induced peripheral neuropathy, or CIPN (1 trial)
• Breast cancer (1 trial)
• Asthma (1 trial)
• Birdshot chorioretinitis (1 trial)

Healthy volunteers have fewer immediate July opportunities because none of the nine new openings includes them. However, the citywide total of 72 recruiting healthy-volunteer trials gives people without a diagnosed condition several options to investigate. Screening requirements can include age limits, medication restrictions, laboratory testing, and scheduled visits.

Large Phase 2 and Phase 3 studies open locally

Portland’s new studies cover dermatology, cystic fibrosis, epilepsy, cancer, and reintegration into civilian life. Drug studies account for 5 of the nine openings, while three are categorized as other and one is behavioral. Six new trials are industry-sponsored, two are classified as other, and one is federally affiliated.

• NCT07700979 is a Phase 3 Akeso study enrolling 900 participants with previously untreated, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. It compares cadonilimab plus chemotherapy with chemotherapy used with or without nivolumab.
• NCT07680790 is Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study, planned for 850 participants with previously untreated, locally advanced, or metastatic EGFR-mutant non-small cell lung cancer. It evaluates izalontamab brengitecan with osimertinib against osimertinib-based comparison treatments.
• NCT07728188 is a Phase 3 AbbVie study involving 520 adults with relapsed or refractory multiple myeloma. The study evaluates injected etentamig plus oral pomalidomide against standard therapies.
• NCT07734415 is a Phase 2 Inmagene LLC study of long-term safety and efficacy for IMG-007 in 400 participants with moderate-to-severe atopic dermatitis.
• NCT07696338, sponsored by Nicole Hamblett, is a cystic fibrosis study planned for 405 participants. The REACT trial includes randomized studies of hypertonic saline and dornase alfa airway-clearance therapies.
• NCT07690436 is an AstraZeneca pilot study planned for 500 adults with transthyretin amyloid cardiomyopathy or heart-failure controls. It examines retinal fundus and OCT imaging for ocular detection of ATTR-CM.

Other July conditions include eczema, juvenile myoclonic epilepsy, muscle-invasive bladder urothelial carcinoma, and reintegration into civilian life. The monthly opening count has moved from 21 in February to 12 in March, 14 in April, 15 in May, 15 in June, and nine in July; the dataset also lists three openings for August.

OHSU and Providence sites offer the broadest local access

Portland’s trial activity is concentrated among Oregon Health & Science University and Providence facilities. OHSU-related listings account for the largest numbers, spanning cancer care, specialty medicine, neurology, pulmonary research, and other academic programs.

• Oregon Health and Science University (190 trials)
• Oregon Health & Science University (150 trials)
• Providence Portland Medical Center (125 trials)
• Providence Saint Vincent Medical Center (93 trials)
• OHSU Knight Cancer Institute (40 trials)
• Research Site (34 trials)
• Providence St. Vincent Medical Center (25 trials)
• Legacy Good Samaritan Hospital and Medical Center (23 trials)
• Oregon Health Sciences University (21 trials)
• VA Portland Health Care System, Portland, OR (20 trials)
• Kaiser Permanente Northwest (19 trials)
• Legacy Emanuel Children’s Hospital (19 trials)

The repeated OHSU and Providence entries may represent separate registry listings or affiliated site records, so applicants should verify the exact location with the study contact. OHSU Knight Cancer Institute is particularly relevant for people seeking oncology research, while Legacy Emanuel Children’s Hospital is a local option for pediatric studies.

Who may qualify in July

Two of the nine new trials include children, and eight include older adults. No new July study is limited exclusively to female or male participants. The new-trial condition mix includes two separate atopic-dermatitis or eczema listings, as well as studies for cystic fibrosis, gastric or gastroesophageal junction cancer, juvenile myoclonic epilepsy, bladder cancer, lung cancer, multiple myeloma, and civilian reintegration.

People who do not find a suitable Portland site can also check Hillsboro and Springfield, which each have 1 recruiting trial listed nearby. Prospective participants should compare eligibility, travel requirements, study visits, and whether the trial is still enrolling before requesting screening.

With late-stage cancer and specialty-disease studies opening at major Portland institutions while dozens of trials approach their closing windows, July is a good time to contact sites rather than wait for a later month. The August pipeline currently shows 3 new openings, so eligible participants may benefit from reviewing active options now and monitoring Portland’s research calendar as the summer progresses.